Filter Results
Clinical Studies
Results filtered:Study status:
Closed for Enrollment
Closed for Enrollment
-
A Phase 2 Open-Label Pilot Study Of The Safety And Tolerability Of Ixazomib Administered Orally To Patients With Scleroderma−Related Interstitial Lung Disease
Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate the safety and tolerability of ixazomib in patients with scleroderma.
-
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study To Evaluate The Efficacy And Safety Of KD025 In Subjects With Diffuse Cutaneous Systemic Sclerosis
Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate the effectiveness and safety of KD025 to treat Diffuse Cutaneous Systemic Sclerosis.
-
A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy And Safety Study Of At Least 48 Weeks Of Oral BI 685509 Treatment In Adults With Early Progressive Diffuse Cutaneous Systemic Sclerosis
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to find out whether BI 685509 helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems.
.